EA201171429A1 - Противораковое соединение и содержащая его фармацевтическая композиция - Google Patents

Противораковое соединение и содержащая его фармацевтическая композиция

Info

Publication number
EA201171429A1
EA201171429A1 EA201171429A EA201171429A EA201171429A1 EA 201171429 A1 EA201171429 A1 EA 201171429A1 EA 201171429 A EA201171429 A EA 201171429A EA 201171429 A EA201171429 A EA 201171429A EA 201171429 A1 EA201171429 A1 EA 201171429A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
pharmaceutical composition
composition containing
tract
tract compound
Prior art date
Application number
EA201171429A
Other languages
English (en)
Other versions
EA021084B1 (ru
Inventor
Жан-Кристоф Карри
Мишель Шев
Франсуа Клерк
Сесиль Комбо
Сильви Гонтье
Ален Крик
Сильветт Лашо
Лоран Шио
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201171429A1 publication Critical patent/EA201171429A1/ru
Publication of EA021084B1 publication Critical patent/EA021084B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к соединению формулы (I), более конкретно, в его левовращающей форме (1а), в частности, имеющему удельное вращение [α] D=-38, 6±0,7 при концентрации 0,698 мг/мл в метаноле. Соединение может существовать в виде основания или соли присоединения кислоты, в частности фармацевтически приемлемой кислоты. Это соединение является селективным ингибитором киназ Aurora А и В. Оно может также применяться в качестве противоракового средства.
EA201171429A 2009-05-18 2010-05-17 Противораковое соединение и содержащая его фармацевтическая композиция EA021084B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902392A FR2945535B1 (fr) 2009-05-18 2009-05-18 Compose anticancereux et composition pharmaceutique le contenant
PCT/FR2010/050948 WO2010133794A1 (fr) 2009-05-18 2010-05-17 Compose anticancéreux et composition pharmaceutique le contenant

Publications (2)

Publication Number Publication Date
EA201171429A1 true EA201171429A1 (ru) 2012-05-30
EA021084B1 EA021084B1 (ru) 2015-04-30

Family

ID=40973187

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171429A EA021084B1 (ru) 2009-05-18 2010-05-17 Противораковое соединение и содержащая его фармацевтическая композиция

Country Status (35)

Country Link
US (2) US9073917B2 (ru)
EP (1) EP2432766B1 (ru)
JP (1) JP5656981B2 (ru)
KR (1) KR20120032483A (ru)
CN (1) CN102459193B (ru)
AR (1) AR076686A1 (ru)
AU (1) AU2010251013B2 (ru)
BR (1) BRPI1012201A2 (ru)
CA (1) CA2762233C (ru)
CL (1) CL2011002930A1 (ru)
CO (1) CO6400138A2 (ru)
CY (1) CY1114850T1 (ru)
DK (1) DK2432766T3 (ru)
EA (1) EA021084B1 (ru)
ES (1) ES2430989T3 (ru)
FR (1) FR2945535B1 (ru)
HK (1) HK1167388A1 (ru)
HR (1) HRP20130959T1 (ru)
IL (1) IL216361A0 (ru)
JO (1) JO2852B1 (ru)
MA (1) MA33356B1 (ru)
ME (1) ME01542B (ru)
MX (1) MX2011012356A (ru)
MY (1) MY152995A (ru)
NZ (1) NZ596464A (ru)
PL (1) PL2432766T3 (ru)
PT (1) PT2432766E (ru)
RS (1) RS53002B (ru)
SG (1) SG176169A1 (ru)
SI (1) SI2432766T1 (ru)
SM (1) SMT201400005B (ru)
TW (1) TWI441822B (ru)
UY (1) UY32644A (ru)
WO (1) WO2010133794A1 (ru)
ZA (1) ZA201108447B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
PT2909204T (pt) 2012-10-12 2019-03-21 Dana Farber Cancer Inst Inc Inibidores de gsk3 e métodos de utilização dos mesmos
EP3164388A1 (en) 2014-07-01 2017-05-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
CN110958882B (zh) 2017-04-05 2023-08-29 布罗德研究所股份有限公司 作为糖原合酶激酶3(gsk3)抑制剂的三环化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005016A (es) 1999-11-19 2003-01-28 Abbott Lab Abridores de canal de potasio de dihidropirimidina triciclica.
KR20030076650A (ko) 2001-02-02 2003-09-26 미쯔비시 웰 파마 가부시키가이샤 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
CA2528938A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
SI1746097T1 (sl) 2005-07-20 2010-05-31 Aventis Pharma Sa dihidropiridin kondenzirani heterocikli postopek za njihovo pripravo njihova uporaba in sestavki ki jih vsebujejo
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
MX2011012356A (es) 2011-12-14
WO2010133794A1 (fr) 2010-11-25
JP5656981B2 (ja) 2015-01-21
DK2432766T3 (da) 2013-10-28
EP2432766B1 (fr) 2013-07-17
JO2852B1 (en) 2015-03-15
MA33356B1 (fr) 2012-06-01
HK1167388A1 (en) 2012-11-30
US9221817B2 (en) 2015-12-29
EP2432766A1 (fr) 2012-03-28
SG176169A1 (en) 2011-12-29
NZ596464A (en) 2014-01-31
CN102459193B (zh) 2014-08-27
CA2762233C (fr) 2017-11-28
SI2432766T1 (sl) 2013-11-29
CY1114850T1 (el) 2016-12-14
MY152995A (en) 2014-12-31
CA2762233A1 (fr) 2010-11-25
AR076686A1 (es) 2011-06-29
HRP20130959T1 (hr) 2013-11-22
FR2945535B1 (fr) 2011-06-10
KR20120032483A (ko) 2012-04-05
US20120220621A1 (en) 2012-08-30
ME01542B (me) 2014-04-20
EA021084B1 (ru) 2015-04-30
TW201100418A (en) 2011-01-01
RS53002B (en) 2014-04-30
CL2011002930A1 (es) 2012-06-29
UY32644A (es) 2010-12-31
CN102459193A (zh) 2012-05-16
AU2010251013A1 (en) 2011-12-08
FR2945535A1 (fr) 2010-11-19
PL2432766T3 (pl) 2013-12-31
TWI441822B (zh) 2014-06-21
ES2430989T3 (es) 2013-11-22
BRPI1012201A2 (pt) 2016-04-05
CO6400138A2 (es) 2012-03-15
IL216361A0 (en) 2012-01-31
JP2012527436A (ja) 2012-11-08
PT2432766E (pt) 2013-10-23
US9073917B2 (en) 2015-07-07
SMT201400005B (it) 2014-03-07
AU2010251013B2 (en) 2015-08-20
ZA201108447B (en) 2013-01-30
US20150266877A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
EA200601802A1 (ru) Производные морфолина
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200600973A1 (ru) ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
EA200970156A1 (ru) Пиридизиноновые производные
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
UA94052C2 (ru) Производные пиридазина
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
EA200970486A1 (ru) Соединения для ингибирования митоза
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
EA201171429A1 (ru) Противораковое соединение и содержащая его фармацевтическая композиция
DE602005020314D1 (de) Bicyclononen-derivate als renin-inhibitoren
EA200970506A1 (ru) Применение индазолметоксиалкановой кислоты для снижения уровней триглицеридов, холестерина и глюкозы
EA200801137A1 (ru) Соединения для ингибирования апоптоза
TW200635581A (en) Formulations of azetidine derivatives which can be injected or administered orally
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU